---
title: "Why Ionis Pharmaceuticals Shares Are Up After Q2 Report"
description: "Ionis posted Q2 EPS of 85 cents vs. a 52 cents loss expected, with revenue at $452 million, beating $282.95 million consensus. FY25 revenue guidance raised to $825-$850 million; Tryngolza sales outloo"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/250850112.md"
published_at: "2025-07-30T19:32:46.000Z"
---

# Why Ionis Pharmaceuticals Shares Are Up After Q2 Report

> Ionis posted Q2 EPS of 85 cents vs. a 52 cents loss expected, with revenue at $452 million, beating $282.95 million consensus. FY25 revenue guidance raised to $825-$850 million; Tryngolza sales outlook hiked to $75-$80 million. Missed the rally? Learn exactly where the next leaders are emerging ...

Ionis posted Q2 EPS of 85 cents vs. a 52 cents loss expected, with revenue at $452 million, beating $282.95 million consensus. FY25 revenue guidance raised to $825-$850 million; Tryngolza sales outlook hiked to $75-$80 million. Missed the rally? Learn exactly where the next leaders are emerging ...

### Related Stocks

- [IONS.US - Ionis Pharma](https://longbridge.com/en/quote/IONS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Ionis 将举行 2025 年第四季度和全年财务业绩网络直播 \| IONS 股票新闻 | Ionis 制药公司将于 2 月 25 日上午 11:30（东部时间）举办一次直播网络研讨会，讨论其 2025 年第四季度和全年财务业绩，以及关键项目的最新进展。该网络研讨会将在线提供，回放将在有限时间内可用。Ionis 以其创新的 RNA | [Link](https://longbridge.com/en/news/275602608.md) |
| Ionis 制药的首席执行官出售了股份 | Ionis 制药的首席执行官 Brett P. Monia 于 2026 年 2 月 6 日以加权平均价格 85.7907 美元出售了 29,430 股普通股，总计 2,524,820 美元。此次出售是在 2024 年 8 月 13 日建立 | [Link](https://longbridge.com/en/news/275518338.md) |
| Ionis 制药首席执行官 Brett P. Monia 报告出售普通股 | Ionis 制药公司首席执行官 Brett P. Monia 报告了该公司普通股的出售。完整的文件可通过提供的链接获取。此消息由公共技术公司生成，仅供信息参考，不应被视为财务或法律建议。原始内容于 2026 年 2 月 10 日通过 EDG | [Link](https://longbridge.com/en/news/275517537.md) |
| 专家展望：从 6 位分析师的视角看 Ionis 制药 | 在最新的季度中，6 位分析师对 Ionis Pharmaceuticals（NASDAQ:IONS）给出了混合评级，12 个月的平均目标价为 98.17 美元，较之前的 85.33 美元有所上升。分析师们提高了他们的评级，反映出积极的市场情 | [Link](https://longbridge.com/en/news/275171994.md) |
| Ionis 制药的首席财务官 Elizabeth L. Hougen 报告了普通股的出售 | Ionis 制药首席财务官 Elizabeth L. Hougen 报告了公司普通股的出售。完整的文件可以通过提供的链接获取。此消息由公共技术生成，仅供信息参考，不应被视为财务、投资或法律建议。原始内容由 Ionis 制药于 2026 年  | [Link](https://longbridge.com/en/news/274583284.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.